Viral Genetics Licenses CU Immune Disease Therapeutic Platforms

CU technology enables a new approach to treating cancer, autoimmune disease and infection.
   
Colorado Springs (December 3, 2009). The University of Colorado and Viral Genetics, Inc., (VRAL.PK) recently executed an exclusive license agreement expanding its previous agreement allowing Viral Genetics to develop treatments for autoimmune diseases, graft rejection, HIV, and cancer based on the work of Dr. M. Karen Newell, a professor of biology at the University of Colorado at Colorado Springs.

Newell’s recent work has uncovered a drug target that may offer a new strategy in treating a wide variety of immune-related disorders and diseases. Cancer, HIV, lupus, Type I diabetes and rheumatoid arthritis are all among the disorders that may be treatable using this approach. Newell’s work targets an early interaction in the cascade of events that results in T cell activation, a central component of the body’s immune response. This approach allows for more targeted control over the body’s immune response against its own and other cells.

“We are confident that Viral Genetics has the capacity to develop these technologies into products with significant impact in these fields,” said David Allen, CU Associate Vice President for Technology Transfer.

“This agreement enables us to work towards bringing a diverse array of drug therapies to the market, all based on technology developed by Dr. Newell,” said Viral Genetics CEO Haig Keledjian. “The synergy between our current work with Dr. Newell and this new line of research made this agreement a natural fit.”
About Viral Genetics, Inc.
Headquartered in San Marino, Calif., Viral Genetics discovers and develops drug therapies to treat infectious, autoimmune, and immunological deficiency disorders using its thymus nuclear protein compound (TNP). The company has an exclusive license agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the company) to license technology developed that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. Viral Genetics has formed a wholly owned subsidiary, MetaCytoLytics, Inc, to advance a technology developed by University of Colorado Professor M. Karen Newell called “metabolic disruption technology” (MDT), which focuses on blocking a tumor cell’s ability to generate energy from glucose or from fatty acids. Viral Genetics has an option to acquire exclusive rights to the metabolic disruption technology from the University of Vermont and the University of Colorado. www.viralgenetics.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of VGV-1 in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.